Search

everythinglearnresearchcommunity

for

Search:↓

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

A satirical post where someone claims to have developed a radioactive isotope scalp serum using Polonium-210 that outperforms Minoxidil and finasteride for hair regrowth. The serum reportedly stimulates DNA repair in hair follicles, leading to significant hair density increase, but the post is met with skepticism and concerns about safety.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

Microneedling with verteporfin for hair loss. Users discuss its potential effectiveness.

The user reported tiny hair growth in thinning areas and improved thickness after 56 days of using 1 mg oral finasteride, 2.5 mg oral minoxidil, and a serum with Redensyl, Anagain, Capixyl, and Procapil. They also take supplements and maintain a healthy lifestyle with no noticeable side effects.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

The conversation is about hair loss treatments, specifically the lack of improvement after one year of using oral finasteride and topical minoxidil. Suggestions include switching to stronger medications like dutasteride and oral minoxidil, considering a hair transplant, and possibly using microneedling or tretinoin.

A user shared their one-year progress on dutasteride, noting fuller hair but persistent thinning at the crown. They sought advice on whether to resume minoxidil and in which form, while others inquired about their choice of dutasteride and its effects.

The user experienced anxiety and side effects from topical finasteride and is considering switching to saw palmetto. Another user reported no improvement with saw palmetto and experienced liver issues.

The user has been taking oral Minoxidil (1.25mg/day) for two weeks to treat hair loss, has experienced no side effects, and plans to increase the dose to 2.5mg/day after another two weeks. They are also monitoring their blood pressure and have not noticed any negative interactions with their pre-workout supplements.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.

A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.

A 30-year-old man shared his experience with finasteride, taking 1mg every other day, which led to sexual side effects and other issues, prompting him to stop the treatment despite initial hair improvement. He previously tried natural methods and minoxidil without much success and is now considering a buzzcut.

The post and conversation are about a user's one-year progress in treating hair loss. The user used 1 mg of finasteride daily, foam minoxidil once daily, and 1% ketoconazole shampoo 3-4 times a week. The conclusion is that patience and consistency are important in treating hair loss.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

Exploring treatments for hair loss, such as finasteride, minoxidil, RPB (an unknown acronym), vitamin D levels, and derma rolling.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

Aspirin reduces the effectiveness of minoxidil for hair loss. Quercetin and 5-ASA medications also inhibit the necessary enzyme for minoxidil to work.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

The conversation discusses using pumpkin seed oil, saw palmetto, fo-ti, and astaxanthin for hair loss, with additional use of Nizoral shampoo. Users express skepticism about regrowth and suggest adding a micro derm roller or considering minoxidil and finasteride for better results.

The user started finasteride (1mg) a year ago for hair thinning, experiencing stabilization but not significant regrowth. Suggestions included adding minoxidil, microneedling, and considering a hair transplant for improved results.

_the_orange_box_'s experience using oral minoxidil, with discussion about finasteride and the potential side effects of both treatments. Other users shared their own experiences related to hair loss treatments.

The user shared six months of progress using oral finasteride (1.2mg) and minoxidil (3mg) with positive results. They do not use topical minoxidil and have not experienced side effects like erectile dysfunction.